Previous 10 | Next 10 |
DUBLIN, Ireland , April 2, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET . The conference w...
DUBLIN , March 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd European ...
Between the Christmas lows, when my interview was published and yesterday's Q4/18 results , Protagonist ( PTGX ) had a strong run for a ~50% return. Investors were probably anticipating good news about the PTG-200 development partnership with Janssen - which once again didn't arrive. PTG-...
DUBLIN , March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b /3 study of TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is a n...
Theravance Biopharma, Inc. (TBPH) Q4 2018 Earnings Conference Call February 26, 2019 05:00 p.m. ET Company Representatives Rick Winningham - Chief Executive Officer Brett Haumann - Chief Medical Officer Jessica Stitt - Vice President of Finance Alex Dobbin - Head of Investor Re...
Theravance Biopharma (NASDAQ: TBPH ): Q4 GAAP EPS of -$0.92 beats by $0.14 . Revenue of $15.74M (+248.2% Y/Y) misses by $7.69M . Press Release More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news,
DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2018 . Revenue for the fourth quarter and full year 2018 was $15.7 mil...
DUBLIN , Feb. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET . The conference will...
DUBLIN , Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2018 and provide a business update after market close on Tuesday, Feb...
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...